1.p53 protein expression and its prognostic importance in patients with nodal non-Hodgkin's lymphoma.
Myung Ju AHN ; Hawk KIM ; In Soon KIM ; Jin Kyung PARK ; Mo Ran KI ; Chan Kum PARK
Journal of Korean Medical Science 2000;15(1):59-64
To determine whether the p53 expression might be a predictor for treatment sponse and overall survival in nodal non-Hodgkin's lymphoma (NHL), we analyzed e expression of p53 in 69 NHL patients. p53 protein expression was analyzed by munohistochemistry with long-term follow up (1-148 months: median 12.2). p53 pression was noted in 23/69 (33.3%) patients. Complete response (CR) rate to stemic chemotherapy was correlated with stage (I/II) (p=0.038), but not with 3 expression (p=0.2856). Poor overall survival was associated with stage =0.0010) or IPI score (p=0.0076), but not with p53 expression (p=0.8601). From ratification analysis by stage, in stage III/IV patients, the p53 positive oup had a trend to be associated with poor overall survival than the p53 gative group. Multivariate analysis revealed that p53 positive group was sociated with less CR rate compared to the p53 negative group (p=0.046), ereas overall survival was correlated with stage (p=0.0320), not with p53 atus. p53 expression was associated with less CR rate in patients with DLBL. rther studies with large numbers of samples and homogenous group of NHL are eded to determine the prognostic value of cell cycle regulator, p53 in NHL.
Antibodies, Monoclonal
;
Cell Cycle Proteins/biosynthesis
;
Female
;
Gene Expression
;
Human
;
Immunohistochemistry
;
Immunophenotyping
;
Lymph Nodes/pathology*
;
Lymph Nodes/metabolism*
;
Lymphoma, Non-Hodgkin/pathology*
;
Lymphoma, Non-Hodgkin/metabolism*
;
Lymphoma, Non-Hodgkin/genetics
;
Lymphoma, Non-Hodgkin/drug therapy
;
Male
;
Middle Age/Mpartment of Microbiology
;
Prognosis
;
Protein p53/immunology
;
Protein p53/genetics
;
Protein p53/biosynthesis*
2.Non-Hodgkin's lymphoma of the prostate: a report of 2 cases and review of the literature.
Xiao-Jian SHEN ; Xiao-Gang ZHENG ; Xiao-Jun ZHOU ; Hang-Bo ZHOU
National Journal of Andrology 2007;13(10):895-898
OBJECTIVETo study the clinicopathological characteristics of primary Non-Hodgkin's Lymphoma (NHL) of the prostate.
METHODSTwo cases of primary NHL of the prostate were studied by analyzing the clinical data, pathological features, prognosis and review of the literature.
RESULTSHE showed that the normal prostatic tissues were replaced by diffuse-type cancer tissues composed of oval or round medium- to large- size lymphoid cells, with vesicular nuclei, fine chromatin, 2-4 membrane-bound nucleoli and scanty cytoplasm, with either amphophilic or basophilic. Immunohistochemistry revealed: CD20 +, CD79a +, CD10 -, CD5 -, CD3 - and CD45 - in Case 1 and CD20+ + +, PSA +/-, CKpan -, Syn -, CgA -, 34betaE12 -, P504S - and CD3 - in Case 2. Case 1 received chemotherapy combined with radiotherapy, relapsed 4 years later and stabilized by repeated chemotherapy. Case 2 experienced no recurrence after treated by chemotherapy.
CONCLUSIONSurgical treatment could be avoided by preoperative pathological diagnosis of primary NHL of the prostate, for which combined chemotherapy should be the first preference.
Aged ; Antigens, CD20 ; analysis ; Follow-Up Studies ; Humans ; Immunohistochemistry ; Lymphoma, Non-Hodgkin ; drug therapy ; metabolism ; pathology ; Male ; Middle Aged ; Prognosis ; Prostatic Neoplasms ; drug therapy ; metabolism ; pathology
3.The Non-Squamous Cell Cancers of the Larynx.
Joon Bum JOO ; Seung Joo YOO ; Soon Yuhl NAM ; Sang Yoon KIM
Korean Journal of Otolaryngology - Head and Neck Surgery 2001;44(11):1199-1205
BACKGROUND AND OBJECTIVES: The majority of laryngeal tumors are known to be SCC (squamous cell carcinoma). Non-SCC (non-squamous cell cancers) of the larynx represent a diverse spectrum of diseases with different prognosis and ratio-nales of management from SCC. Therapeutic options to these tumors depend on their histopathological characteristics and clinical behaviors. The purpose of this study was to assess the unique aspects of the non-SCC and to draw diagnosis and provide management options and prognostic variables. MATERIALS AND METHOD: Eleven non-SCC of the larynx from the 212 patients who were diagnosed with larynx cancer during their 3-year visits from 1997 to 2000 were reviewed retrospectively. RESULTS: The incidence of non-SCC was 5.2%. Pathology of non-SCC revealed 3 cases of malignant lymphoma, 2 cases of verrucous cell carcinoma and neuroendocrine carcinoma one case each of basaloid squamous cell carninoma, salivary duct carcinoma, adenocarcinoma, and spindle cell carcinoma. The most common site of origin was supraglottis (6 case, 56.5%), followed by glottis (4 cases, 36.4%) and subglottis (2 cases, 17.2%). Non-Hodgkin's lymphomas and basaloid squamous cell carninoma were treated by chemotherapy. The remaining cases were treated with surgery followed by postoperative radio-therapy or postoperative chemotherapy. The mean follow-up period was 26.8 months (12-43 months). CONCLUSION: Non-SCC accounts for approximately 5.2% of all malignancies of the larynx. Tissue biopsy is the most important diagnostic tool for the non-SCC of the larynx and the tissue sample must be obtained from the deep portion of the submucosal layer. Except for malignant lymphomas, the combined therapy that includes surgery would be the best method of treatment for non-SCC.
Adenocarcinoma
;
Biopsy
;
Carcinoma, Neuroendocrine
;
Diagnosis
;
Drug Therapy
;
Follow-Up Studies
;
Glottis
;
Humans
;
Incidence
;
Laryngeal Neoplasms
;
Larynx*
;
Lymphoma
;
Lymphoma, Non-Hodgkin
;
Pathology
;
Prognosis
;
Retrospective Studies
;
Salivary Ducts
4.Clinical features of 50 cases of primary gastric lymphoma.
Jin HUANG ; Meizuo ZHONG ; Youhong TANG ; Jianhong LU ; Xiaoling LI ; Guiyuan LI
Journal of Central South University(Medical Sciences) 2012;37(10):997-1002
OBJECTIVE:
To analyze the clinical characteristics of primary gastric lymphoma (PGL) and to improve its diagnosis and treatment.
METHODS:
The clinical manifestations, diagnosis, treatments and history of 50 PGL patients, who were hospitalized from September 2005 to September 2009, were reviewed and analyzed.
RESULTS:
The main manifestation of PGL was epigastric pain with infrequent systemic symptoms, such as stomach ache, abdominal discomfort, vomit, black stool, loss of appetite, fever, feeble, and skinny. Pathological examination indicated that only 1 patient had T cell lymphoma while the rest 49 had B cell lymphoma. Fourteen had mucosa-associated lymphoid tissue lymphoma (MALT), 35 had diffuse large B cell lymphoma (DLBCL), and 2 had both DLBCL and MALT (DLBCML). All the 50 patients received chemotherapy, and 12 underwent surgical treatment besides chemotherapy. Fourteen out of the 49 patients with B cell lymphoma received rituximab together with chemotherapy, and 35 received chemotherapy alone. The 2-year survival rate in the patients receiving rituximab together with chemotherapy was higher than that in the patients receiving chemotherapy alone (85.7% vs 77.1%, P< 0.05). The 2-year survival rate in patients of clinical stage I-II was higher than that in patients of clinical stage III-IV (90.9% vs 71.4%, P< 0.05).
CONCLUSION
The main clinical manifestation of PGL patients is non-specific gastrointestinal symptoms, among which abdominal pain is most common. The clinical examination mainly relies on pathological examinations, and the most common pathological type of primary gastric lymphoma is DLBCL. The main treatment is chemotherapy, and the prognosis is related to the clinical stage and the use of rituximab. After the treatment, the 2-year survival rate in the 50 patients reaches 80.0%.
Antibodies, Monoclonal, Murine-Derived
;
therapeutic use
;
Humans
;
Lymphoma, B-Cell, Marginal Zone
;
Lymphoma, Large B-Cell, Diffuse
;
Lymphoma, Non-Hodgkin
;
diagnosis
;
drug therapy
;
pathology
;
Prognosis
;
Retrospective Studies
;
Rituximab
;
Stomach Neoplasms
;
diagnosis
;
drug therapy
;
pathology
;
Survival Rate
5.Bendamustine plus rituximab as first-line treatment in patients with indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma : a real-world study in China.
Kai Xin DU ; Hao Rui SHEN ; Li WANG ; Jin Hua LIANG ; Jia Zhu WU ; Yue LI ; Yi XIA ; Hua YIN ; Jian Yong LI ; Wei XU
Chinese Journal of Hematology 2023;44(4):333-336
6.Expression of cyclin-dependent kinase inhibitor p27kip1 in malignant lymphomas.
Journal of Korean Medical Science 2000;15(4):399-406
p27kip1 is a cyclin-dependent kinase inhibitor that regulates progression from G1 into S phase. Aberrations in cell cycle control are often observed in tumors d might even be necessary in tumor development. Recent reports showed that low 7kip1 expression is associated with poor prognosis in several tumors and ukemia. To investigate the expression of p27kip1 in malignant lymphomas and ucidate the role of p27kip1 as a possible prognostic indicator, the authors rformed an immunohistochemical staining of p27kip1 correlated with Ki-67 belling index and clinical parameters. p27kip1 expression was reduced variably most malignant lymphomas and inversely correlated with Ki-67 labelling index +AD0-0.0151). Regarding chemotherapeutic response, p271kip1 expression in the mplete remission group showed statistically significant difference in pression compared to the progressive disease group (p+AD0-0.0021). There were gnificant differences in survival between cases with low and high p27kip1 pression (p+AD0-0.0071). In a multivariate Cox analysis, p27kip1 expression was dependent prognostic factors as well as other known prognostic factors cluding age, grade, stage and chemotherapeutic response. In conclusion, the udy suggests that reduced expression of p27kip1 protein may play a role in the thogenesis and biologically aggressive behavior of malignant lymphomas.
Adolescence
;
Adult
;
Aged
;
Antineoplastic Agents, Combined/therapeutic use
;
Cell Cycle
;
Cell Division
;
Child
;
Child, Preschool
;
Comparative Study
;
Female
;
Follow-Up Studies
;
Human
;
Ki-67 Antigen/analysis
;
Life Tables
;
Lymphoma, Non-Hodgkin/pathology
;
Lymphoma, Non-Hodgkin/mortality
;
Lymphoma, Non-Hodgkin/drug therapy
;
Lymphoma, Non-Hodgkin/chemistry+ACo-
;
Male
;
Microtubule-Associated Proteins/physiology
;
Microtubule-Associated Proteins/analysis+ACo-
;
Middle Age
;
Neoplasm Proteins/physiology
;
Neoplasm Proteins/analysis+ACo-
;
Prognosis
;
Proportional Hazards Models
;
Survival Analysis
;
Treatment Outcome
7.Expression of cyclin-dependent kinase inhibitor p27kip1 in malignant lymphomas.
Journal of Korean Medical Science 2000;15(4):399-406
p27kip1 is a cyclin-dependent kinase inhibitor that regulates progression from G1 into S phase. Aberrations in cell cycle control are often observed in tumors d might even be necessary in tumor development. Recent reports showed that low 7kip1 expression is associated with poor prognosis in several tumors and ukemia. To investigate the expression of p27kip1 in malignant lymphomas and ucidate the role of p27kip1 as a possible prognostic indicator, the authors rformed an immunohistochemical staining of p27kip1 correlated with Ki-67 belling index and clinical parameters. p27kip1 expression was reduced variably most malignant lymphomas and inversely correlated with Ki-67 labelling index +AD0-0.0151). Regarding chemotherapeutic response, p271kip1 expression in the mplete remission group showed statistically significant difference in pression compared to the progressive disease group (p+AD0-0.0021). There were gnificant differences in survival between cases with low and high p27kip1 pression (p+AD0-0.0071). In a multivariate Cox analysis, p27kip1 expression was dependent prognostic factors as well as other known prognostic factors cluding age, grade, stage and chemotherapeutic response. In conclusion, the udy suggests that reduced expression of p27kip1 protein may play a role in the thogenesis and biologically aggressive behavior of malignant lymphomas.
Adolescence
;
Adult
;
Aged
;
Antineoplastic Agents, Combined/therapeutic use
;
Cell Cycle
;
Cell Division
;
Child
;
Child, Preschool
;
Comparative Study
;
Female
;
Follow-Up Studies
;
Human
;
Ki-67 Antigen/analysis
;
Life Tables
;
Lymphoma, Non-Hodgkin/pathology
;
Lymphoma, Non-Hodgkin/mortality
;
Lymphoma, Non-Hodgkin/drug therapy
;
Lymphoma, Non-Hodgkin/chemistry+ACo-
;
Male
;
Microtubule-Associated Proteins/physiology
;
Microtubule-Associated Proteins/analysis+ACo-
;
Middle Age
;
Neoplasm Proteins/physiology
;
Neoplasm Proteins/analysis+ACo-
;
Prognosis
;
Proportional Hazards Models
;
Survival Analysis
;
Treatment Outcome
8.Non-Hodgkin's lymphoma with pulmonary infiltrates simulating tuberculoma.
Tae Young YANG ; Je Jung LEE ; Hyeong Cheon PARK ; Yeo Kyeoung KIM ; Ho In HWANG ; Sang Hee CHO ; Moo Rim PARK ; Ik Joo CHUNG ; Hyeoung Joon KIM
Korean Journal of Medicine 2002;62(1):109-113
We report a 63-years-old woman who developed a nodular lesion in right upper lobe (RUL) of lung after achieving a partial response with salvage chemotherapy for relapsed non-Hodgkin's lymphoma (NHL). Previously, she had been diagnosed as NHL and tuberculous lymphadenitis resulting a complete response with 8 cycles of CHOP regimen and anti-tuberculosis medication for 1 year. CT scan of the chest showed an irregular marginated soft tissue density in RUL with internal punctate calcifications and this lesion was difficult to discriminate between pulmonary tuberculosis and parenchymal involvement of NHL. Because the pulmonary infiltrations progressed despite empirical anti-tuberculosis medication, we performed bronchoscopic biopsy, showing diffuse large B-cell lymphoma. Thereafter, the pulmonary infiltrations were markedly improved with salvage chemotherapy. However, she died of refractory NHL despite high-dose chemotherapy with autologous peripheral blood stem cell transplantation.
Biopsy
;
Diagnosis
;
Drug Therapy
;
Female
;
Humans
;
Lung
;
Lymphoma
;
Lymphoma, B-Cell
;
Lymphoma, Non-Hodgkin*
;
Pathology
;
Peripheral Blood Stem Cell Transplantation
;
Thorax
;
Tomography, X-Ray Computed
;
Tuberculoma*
;
Tuberculosis
;
Tuberculosis, Lymph Node
;
Tuberculosis, Pulmonary
9.Autoimmune Hemolytic Anemia in a Patient with Primary Ovarian Non-Hodgkin's Lymphoma.
Chang Kil JUNG ; Jong Seung PARK ; Eun Ju LEE ; Sung Hyun KIM ; Hyuk Chan KWON ; Jae Seok KIM ; Mee Sook ROH ; Seoung Kook YOON ; Kyeong Hee KIM ; Jin Yeong HAN ; Hyo Jin KIM
Journal of Korean Medical Science 2004;19(2):294-296
The primary ovarian lymphoma is a rare disease with poor prognosis. The incidence of autoimmune hemolytic anemia in patients with non-Hodgkin's lymphoma is estimated at 3%. However, a substantial portion of the previously reported cases of ovarian lymphoma actually represented ovarian involvement by more diffuse lymphomatous process. If stringent criteria are used for case selection, true primary ovarian lymphoma usually carries a favorable prognosis. We present a primary malignant lymphoma of ovary accompanied by autoimmune hemolytic anemia in a 29-yr-old patient. After ablative surgery, the hemoglobin level and the reticulocyte count were normalized. One year following surgery and chemotherapy, the patient is alive and disease free.
Adult
;
Anemia, Hemolytic/*immunology
;
Antineoplastic Agents, Hormonal/therapeutic use
;
Autoimmune Diseases/immunology
;
Combined Modality Therapy
;
Female
;
Human
;
Lymphoma, Non-Hodgkin/*complications/drug therapy/pathology/surgery
;
Ovarian Neoplasms/*complications/drug therapy/pathology/surgery
;
Prednisolone/therapeutic use
10.Clinicopathological features and prognostic factors of 216 cases with primary gastrointestinal tract non-Hodgkin's lymphoma.
Wen-juan YIN ; Mei-juan WU ; Hai-yan YANG ; Xiu ZHU ; Wen-yong SUN
Chinese Journal of Hematology 2013;34(5):377-382
OBJECTIVETo investigate the clinicopathological features of primary gastrointestinal non-Hodgkin's lymphomas (PGI-NHL) and their prognostic values.
METHODSThe clinical and pathological data of 216 patients diagnosed as PGI-NHL from Zhejiang Cancer Hospital were analyzed retrospectively. χ² test, log-liner model analysis, COX proportional hazard regression analysis and Life-table survival analysis were used to analyze the survival status of the patients by SAS 8.2 software, and Log-rank test was performed to couple the overall survival rates with different prognostic factors.
RESULTSTotally, the age of onset was 8 to 89 years with the median age of 56.5 years. Male versus female was 1.27∶1(121∶95). The most frequently involved location was stomach (147 cases, 68.1%), followed by ileocecus (25 cases, 11.6%), large intestine (20 cases, 9.3%), small intestine (17 cases, 7.9%) and multiple GI involvement (5 cases, 2.3%). 182 cases were classified as B cell lymphomas, 22 cases as T cell lymphomas, and 12 cases not classified exactly due to insufficient data. The 3-year and 5-year survival rates of the patients were 69.4% and 53.3%, respectively. Univariate analysis revealed that age>60 years, ECOG≥2, high LDH level, stage Ⅲ-Ⅳ, IPI≥2, T cell type and intestinal involvement were predictors for poor prognosis. IPI≥2, T cell type and intestinal involvement were independent adverse predictors for prognosis by multiple COX proportional hazard regression analysis. Among different treatment groups, cases received chemotherapy combined with local radiotherapy gained the best survival status.
CONCLUSIONB-cell lymphoma was the main pathological type in PGI-NHL; IPI≥2, T-cell type and intestinal involvement are independent adverse predictors for prognosis; chemotherapy combined with local radiotherapy might be the choice of approach for advanced stage and aggressive PGI-HNL.
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Child ; Female ; Follow-Up Studies ; Gastrointestinal Neoplasms ; drug therapy ; pathology ; Humans ; Lymphoma, Non-Hodgkin ; drug therapy ; pathology ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Young Adult